Increased risk of venous thromboembolism in splenectomized patients with sickle cell disease

Juliette Tennenbaum¹, Geoffroy Volle², Jacques Pouchot¹, Laure Joseph^{3

4}, Djamal Khimoud¹, Brigitte Ranque^{1

4}, Jean-Benoît Arlet^{1

4

5}

Affiliations

¹ French National Reference Center for sickle cell disease, thalassaemia and other red blood cell and erythropoiesis disorders, Department of Internal Medicine, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris-Cité University Paris, Paris, France.
² Department of Internal Medicine, Henri-Mondor Hospital, AP-HP, Paris Est University, Créteil, France.
³ Reference Center for sickle cell disease, thalassemia and other red blood cell and erythropoiesis disorders, Biotherapy department, Necker Hospital, AP-HP, Paris-Cité University, Paris, France.
⁴ Laboratory of Excellence GR-Ex, Paris-Cité University, Paris, France.
⁵ INSERM U1163, CNRS 8254, IMAGINE Institute, Paris-Cité University, Paris, France.

Juliette Tennenbaum et al. Br J Haematol. 2023 May.

. 2023 May;201(4):793-796.

doi: 10.1111/bjh.18743. Epub 2023 Mar 14.

Juliette Tennenbaum¹, Geoffroy Volle², Jacques Pouchot¹, Laure Joseph^{3

4}, Djamal Khimoud¹, Brigitte Ranque^{1

4}, Jean-Benoît Arlet^{1

4

5}

¹ French National Reference Center for sickle cell disease, thalassaemia and other red blood cell and erythropoiesis disorders, Department of Internal Medicine, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris-Cité University Paris, Paris, France.
² Department of Internal Medicine, Henri-Mondor Hospital, AP-HP, Paris Est University, Créteil, France.
³ Reference Center for sickle cell disease, thalassemia and other red blood cell and erythropoiesis disorders, Biotherapy department, Necker Hospital, AP-HP, Paris-Cité University, Paris, France.
⁴ Laboratory of Excellence GR-Ex, Paris-Cité University, Paris, France.
⁵ INSERM U1163, CNRS 8254, IMAGINE Institute, Paris-Cité University, Paris, France.

No abstract available

Keywords: Sickle cell disease; hyposplenism; pulmonary embolism; splenectomy; venous thromboembolism.

References

1. Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol. 2014;166:165-76.
1. Pinto VM, Gianesin B, Piel FB, Longo F, Rigano P, Quota A, et al. Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting. Haematologica. 2022; Epub ahead of print.
1. Wright JG, Hambleton IR, Thomas PW, Duncan ND, Venugopal S, Serjeant GR. Postsplenectomy course in homozygous sickle cell disease. J Pediatr. 1999;134:6-309.
1. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sørensen HT. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost. 2010;8:1413-6.
1. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009;114:2861-8.